Across TCGA pan-cancer cohorts, IGLV3-10 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated IGLV3-10 data layer compared with 18 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher IGLV3-10 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IGLV3-10 expression acts as an unfavorable survival marker.

LUAD and DLBC are the cancer types where IGLV3-10 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.214	0.685	.001	15	view →
DLBC	OS	Median	All	0.054	0.842	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: IGLV3-10 tumor-vs-normal RNA expression · all IGLV3-10 data types